Answers are grounded in this paper and cite their sources.
The majority of established prognostic factors for multiple myeloma (MM) are not modifiable and include cytogenetic abnormalities, beta-2 microglobulin, lactate dehydrogenase, age, and Eastern Cooperative Oncology Group (ECOG) performance status [ 1 , 2 ]. There is a lack of evidence-based clinical interventions available to complement existing treatment modalities to improve prognostic trajectories.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: